MA-ECHOSENS
14.12.2021 15:56:07 CET | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan® portfolio of solutions, is pleased to celebrate its 20th consecutive year pioneering the field of liver diagnosis and management. Recognized worldwide as the reference for liver fibrosis and liver steatosis assessment, with more than 3,000+ peer-reviewed publications and 140+ international guidelines, Echosens continues to show an unparalleled commitment to innovation. In the past year alone Echosens launched three new global products all carefully designed to optimize the overall FibroScan experience.
A year ago, Echosens launched their flagship and most advanced product, the FibroScan Expert 630 . This device is the complete non-invasive solution for liver disease management, powered by liver stiffness measurement (LSM by VCTE) CAP and spleen stiffness measurement (SSM by VCTE) as part of an overall assessment of the liver.
Echosens then launched SmartExam software , which unlocks three key benefits for users: improved reliability in the diagnosis and monitoring of steatosis with continuous CAP; extended usage among severely obese patients with deeper assessment of liver fibrosis and steatosis; and task automation features that enable physicians to dedicate more time to patient care.
Recently, Echosens launched FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. Included on the free myFibroScan app, users can now assess a patient's liver health in just a few clicks, making interpreting results quicker and easier than ever.
“Our long-term commitment to innovation optimizes the FibroScan portfolio of solutions, representing a major step toward winning the worldwide battle against liver disease,” says Dominique Legros, Group CEO, Echosens. “We’re highly grateful to our team leaders and champions for continuing to challenge the status quo in improving the management of silent, underdiagnosed chronic liver disease, which includes NAFLD and its more severe form nonalcoholic steatohepatitis (NASH). A number of chronic liver diseases can be reversible if diagnosed early.”
He points to the FibroScan Expert 630 as an innovative tool designed to expand clinical capabilities in liver health assessment with the addition of SSM by VCTE. This tool potentially supplies a cost-effective, non-invasive modality for spleen and liver stiffness measurements that may be used as an aid in the diagnosis, monitoring and clinical management of adult patients with liver disease.
For more than two decades, Echosens has generated robust clinical data that is extremely valuable in helping providers, benefits decision-makers and payers understand how a point-of-care examination can improve the quality of specialist referrals – reducing waste from unnecessary and often invasive testing. This was validated in an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) and published in the September 2021 issue of the American Journal of Managed Care .
“Furthermore, the National Institute for Health and Care Excellence (NICE ), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary care setting ,” says Legros. “Additionally, new guidelines from the European Association for the Study of the Liver (EASL), a professional association for those researching liver disease, outlined an unprecedented level of recommendation for Echosens’ solutions.”
Jon Gingrich, CEO, Echosens North America, states, “During our anniversary year, it is gratifying to highlight the exciting technological advances we have developed and introduced to the healthcare industry. We have demonstrated our commitment to innovation and value in the field, reflected by the essential and actionable data to support and advance liver health management.”
Listen to episodes of eHealth Radio Network , featuring some of today’s leading innovators in healthcare and wellness.
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005010/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom